Efficacy News and Research

RSS
Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

New method to identify pathogenic strains that cause pneumonia

New method to identify pathogenic strains that cause pneumonia

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

New approach delivers RNA drugs to silence malfunctioning genes

New approach delivers RNA drugs to silence malfunctioning genes

Kessler Foundation scientists receive more than $1.2 M grants from NJ Commission for SCI research

Kessler Foundation scientists receive more than $1.2 M grants from NJ Commission for SCI research

Glythera secures £700k to advance development of new generation of biological therapeutics

Glythera secures £700k to advance development of new generation of biological therapeutics

Cancer immunotherapies promise to be a new tool in fight against cancer

Cancer immunotherapies promise to be a new tool in fight against cancer

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Oncologist urges drug companies to include key information in cancer drug labels

Oncologist urges drug companies to include key information in cancer drug labels

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Updated EULAR recommendations for management of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.